Literature DB >> 11434509

Nicotine metabolism and CYP2A6 allele frequencies in Koreans.

J T Kwon1, M Nakajima, S Chai, Y K Yom, H K Kim, H Yamazaki, D R Sohn, T Yamamoto, Y Kuroiwa, T Yokoi.   

Abstract

CYP2A6 is a major catalyst of nicotine metabolism to cotinine. Previously, we demonstrated that the interindividual difference in nicotine metabolism is related to a genetic polymorphism of the CYP2A6 gene in Japanese. To clarify the ethnic differences in nicotine metabolism and frequencies of CYP2A6 alleles, we studied nicotine metabolism and the CYP2A6 genotype in 209 Koreans. The cotinine/nicotine ratio of the plasma concentration 2 h after chewing one piece of nicotine gum was calculated as an index of nicotine metabolism. The genotypes of CYP2A6 gene (CYP2A6*1A, CYP2A6*1B, CYP2A6*2, CYP2A6*3, CYP2A6*4 and CYP2A6*5) were determined by polymerase chain reaction (PCR)-restriction fragment length polymorphism or allele specific (AS)-PCR. There were ethnic differences in the allele frequencies of CYP2A6*1A, CYP2A6*1B, CYP2A6*4 and CYP2A6*5 between Koreans (45.7%, 42.8%, 11.0% and 0.5%, respectively) and Japanese (42.4%, 37.5%, 20.1% and 0%, respectively, our previous data). Similar to the Japanese, no CYP2A6*2 and CYP2A6*3 alleles were found in Koreans. The homozygotes of the CYP2A6*4 allele (four subjects) were completely deficient in cotinine formation, being consistent with the data among Japanese. The heterozygotes of CYP2A6*4 tended to possess a lower metabolic ratio (CYP2A6*1A/CYP2A6*4, 4.79 +/- 3.17; CYP2A6*1B/CYP2A6*4, 7.43 +/- 4.97) than that in subjects without the allele (CYP2A6*1A/CYP2A6*1A, 7.42 +/- 6.56; CYP2A6*1A/CYP2A6*1B, 9.85 +/- 16.12; CYP2A6*1B/CYP2A6*1B, 11.33 +/- 9.33). The subjects who possess the CYP2A6*1B allele appeared to show higher capabilities of cotinine formation. It was confirmed that the interindividual difference in nicotine metabolism was closely related to the genetic polymorphism of CYP2A6. The probit plot of the metabolic ratios in Koreans (8.73 +/- 11.88) was shifted to a higher ratio than that in the Japanese (3.78 +/- 3.09). In each genotype group, the Korean subjects revealed significantly higher metabolic ratios than the Japanese subjects. The ethnic difference in cotinine formation might be due to environmental and/or diet factors as well as genetic factors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11434509     DOI: 10.1097/00008571-200106000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  17 in total

1.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.

Authors:  Ryoko Yoshida; Miki Nakajima; Yuki Watanabe; Jun-Tack Kwon; Tsuyoshi Yokoi
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

2.  A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.

Authors:  Young-Woo Kim; Mi-Jung Kim; Keun Won Ryu; Hyeong-Seok Lim; Jun Ho Lee; Sun-Young Kong; Jong Seok Lee; Il Ju Choi; Chan Gyoo Kim; Jong Yeul Lee; Soo-Jeong Cho; Myeong-Cherl Kook; Young-Iee Park; Seok-Ki Kim; Sook Ryun Park
Journal:  Gastric Cancer       Date:  2015-04-08       Impact factor: 7.370

3.  Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.

Authors:  Jae Ho Jeong; Sook Ryun Park; Yongchel Ahn; Min-Hee Ryu; Baek-Yeol Ryoo; Sun-Young Kong; Jeong Hwan Yook; Moon-Won Yoo; Beom Su Kim; Byung Sik Kim; Yoon-Koo Kang
Journal:  Gastric Cancer       Date:  2015-12-29       Impact factor: 7.370

4.  Intraindividual covariation between e-cigarette and combustible cigarette use in Korean American emerging adults.

Authors:  Jimi Huh; Adam M Leventhal
Journal:  Psychol Addict Behav       Date:  2015-11-30

5.  Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.

Authors:  Taku Nagano; Makiko Shimizu; Kazuma Kiyotani; Tetsuya Kamataki; Ryohji Takano; Norie Murayama; Fumiaki Shono; Hiroshi Yamazaki
Journal:  Int J Environ Res Public Health       Date:  2010-07-20       Impact factor: 3.390

6.  Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling.

Authors:  Hiroshi Yamazaki; Kana Horiuchi; Ryohji Takano; Taku Nagano; Makiko Shimizu; Masato Kitajima; Norie Murayama; Fumiaki Shono
Journal:  Int J Environ Res Public Health       Date:  2010-09-01       Impact factor: 3.390

7.  CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking.

Authors:  Wiratchanee Mahavorasirikul; Wichittra Tassaneeyakul; Soisagwan Satarug; Ronnatrai Reungweerayut; Chacrin Na-Bangchang; Kesara Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  2008-12-13       Impact factor: 2.953

8.  Preliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria.

Authors:  Papichaya Phompradit; Poonuch Muhamad; Anurak Cheoymang; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2014-06-02       Impact factor: 2.345

9.  Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.

Authors:  M I Veiga; S Asimus; P E Ferreira; J P Martins; I Cavaco; V Ribeiro; T N Hai; M G Petzold; A Björkman; M Ashton; J P Gil
Journal:  Eur J Clin Pharmacol       Date:  2008-11-01       Impact factor: 2.953

10.  Urine Cotinine for Assessing Tobacco Smoke Exposure in Korean: Analysis of the Korea National Health and Nutrition Examination Survey (KNHANES).

Authors:  Sungmo Jung; In Seon Lee; Sae Byol Kim; Chan Soo Moon; Ji Ye Jung; Young Ae Kang; Moo Suk Park; Young Sam Kim; Se Kyu Kim; Joon Chang; Eun Young Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.